Log in

Past Fellowship Postings

Purpose

The purpose of the Fellowship Program is to build, in collaboration with industry, Canadian capacity and expertise in the area of oncology and to promote excellence in research through training awards. The goals of the program are to provide an opportunity for individuals who have completed their Medical Oncology training in Canada to have additional clinical and/or fundamental research experience.

Past Recipients

2018

Dr. Michael Raphael
VOLUME-OUTCOME ASSOCIATION FOR THE SYSTEMIC TREATMENT OF CANCER: A POPULATION BASED STUDY   

2017

Dr. Doreen Ezeife
ESTABLISHING A LEVEL PLAYING FIELD: DEVELOPMENT OF A VALUE ASSESSMENT FRAMEWORK FOR ONCOLOGY DRUGS 

 

2016

Dr. Jonathan LOREE
IMPACT OF INTRATUMOR HETEROGENEITY AND LOW FREQUENCY RAS MUTATIONS ON CLINICAL OUTCOME IN COLORECTAL CANCER

2015

Dr. Katarzyna JERZAK
THYROID HORMONE RECEPTORS IN BREAST CANCER- PROGNOSTIC, PREDICTIVE AND THERAPEUTIC IMPLICATIONS

Dr. Sunil PARIMI
GENOMIC PROFILING OF CIRCULATING TUMOR DNA (CTDNA) AS A PREDICTIVE BIOMARKER FOR PATIENTS WITH CASTRATION RESISTANT PROSTATE CANCER

2014

Dr. Adrian G SACHER
TRANSLATING TARGETED NEXT-GENERATION SEQUENCING INTO A CLINICAL TOOL FOR PERSONALIZED MANAGEMENT OF SQUAMOUS CELL LUNG CANCER

2013

Dr. Nimira ALIMOHAMED
BONE TARGETED THERAPY FOR PROSTATE CANCER IN CANADA: PRACTICE PATTERNS AND IMPACT ON OUTCOMES

Dr. Christine KIM
PREDICTIVE AND PROGNOSTIC IMPACTS OF QUALITY OF LIFE MEASUREMENTS AND BIOMARKER DISCOVERY IN CHEMOTHERAPY TREATED ADVANCED PANCREATIC CANCER PATIENTS IN NORTHERN ALBERTA

Dr. Ravi RAMJEESINGH
ASSOCIATION BETWEEN TIMES TO ADMINISTRATION OF ADJUVANT CHEMOTHERAPY AND OUTCOMES IN EARLY BREAST CANCER: ANALYSIS OF ADJUVANT STUDIES CONDUCTED BY NCIC CLINICAL TRIALS GROUP

2012

Dr. David DAWE
ASSESSMENT OF HEALTH CARE PATTERNS FOR ELDERLY LUNG CANCER PATIENTS IN SOUTHERN ONTARIO

Dr. Tina HSU
PHYSICAL, EMOTIONAL AND SOCIAL STRESSORS AND THEIR IMPACT ON QUALITY OF LIFE OF CAREGIVERS OF ELDERLY PATIENTS WITH CANCER

Dr. Demetrios SIMOS
A PHASE 2 CLINICAL TRIAL EXPLORING THE CLINICAL AND CORRELATIVE EFFECTS OF COMBINING DOXYCYCLINE WITH STANDARD BISPHOSPHONATE THERAPY IN PATIENTS WITH METASTATIC BREAST CANCER (THE ACHILLES STUDY)

2011

Dr. Maria HO
EXPECTATIONS OF CARE FOR YOUNG ADULT SURVIVORS OF CHILDHOOD CANCERS

Dr. Solmaz SAHEBJAM
EVALUATING THE ANTI-TUMOR ACTIVITY OF A DUAL IGF-1R AND IR INHIBITOR (OSI-906) IN GENOMICALLY CHARACTERIZED HUMAN BREAST CANCER (BC) XENOGRAFT MODEL

2010

Dr. Nicole CHAU
UNDERSTANDING MECHANISMS OF RESISTANCE TO EGRF INHIBITORS IN HEAD AND NECK CANCER

Dr. David CESCON
MOLECULAR PATHOGENESIS OF BRCA1-ASSOCIATED AND TRIPLE-NEGATIVE BREAST CANCER: MECHANISM OF TISSUE SPECIFICITY AND IDENTIFICATION AND CHARACTERIZATION OF COOPERATING TUMORIGENIC PATHWAYS

Dr. Vincent TAM
A PHASE II TRIAL COMPARING LOW DOSE METRONOMIC CYCLOPHOSPHAMIDE AND CEDIRANIB TO CYCLOPHOSPHAMIDE AND PLACEBO AS MAINTENANCE THERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER

2009

Andrea MOLCKOVSKY
NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY OF BIOFLUIDS: IDENTIFICATION OF ONCOLOGIC BIOMARKERS

Mateya E TRINKAUS
CLINICAL AND TRANSLATIONAL STUDIES OF HYPOXIA IN SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

Michael VICKERS
PRECLINICAL/CLINICAL EVALUATION OF A CDK4/6 INHIBITOR + 5-FU IN COLON CANCER

2008

Dr. Phil BEDARD
DETERMINANTS OF GENOMIC RISK IN EARLY-STAGE BREAST CANCER

Dr. Janine DAVIES
PHASE IB STUDY OF SORAFENIB FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA AND CHILD’S B CIRRHOSIS

Dr. Leora HORN
A PHASE II TRIAL OF CELECOXIB PLUS CHEMOTHERAPY [DOCETAXEL] OR [PEMETREXED] IN PATIENTS WITH PREVIOUSLY TREATED, ‘COX DEPENDENT’ RECURRENT NON-SMALL CELL LUNG CANCER

Dr. Winson CHEUNG
DISCORDANCES BETWEEN PATIENT AND PHYSICIAN EXPECTATIONS FOR CANCER SURVIVORSHIP CARE

2007

Dr. Orit FREEDMAN
THE DEVELOPMENT OF A PROSPECTIVE, VALIDATED RISK INDEX FOR SKELETAL RELATED EVENTS IN BREAST CANCER PATIENTS WITH BONE METATSTASES

Dr. Howard LIM
A PHASE II STUDY LINE SUNITINIB IN PREVIOUSLY TREATED PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METATSTATIC PANCREATIC CANCER

Dr. Daniel HENG
A PHASE II STUDY OF SORAFENIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (RCC) REFRACTORY TO PRIOR SUNITINIB OR BEVACIZUMAB THERAPY

2006

Dr. Christine SIMMONS
CHANGES IN BREAST TUMOR RECEPTOR STATUS WITH TIME-DOES PERFORMING A CONFIRMATORY BIOPSY AT THE TIME OF METASTIC RECURRENCE ALTER PATIENT MANAGEMENT?

Dr. Heather MCARTHUR
AN OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY PHARMACOKINETICS AND ACTIVITY OF LAPATINIB IN COMBINATION WITH BEVACIZUMB (AVASTIN) IN METASTATIC BREAST CANCER

Jennifer L SPRATLIN
A PHASE I STUDY OF PXD101 IN COMBINATION WITH BORTEZOMIB (PS-341) IN PATIENTS WITH ADVANCED SOLID TUMORS AND LYMPHOMA WITH TRANSLATIONAL RESEARCH COMPONENTS


Canadian Association of Medical Oncologists
1309 Carling Ave
PO Box 35164 Westgate
Ottawa, ON K1Z 1A2

Phone: 613.415.6033
Fax: 866.839.7501
Email: info@camo-acom.ca

Powered by Wild Apricot Membership Software